PolarisQB is utilizing Quantum Computing, Artificial Intelligence, Machine Learning and Personalized Medicine to Revolutionize Drug Design. By compressing the lead time for pre-clinical drug candidates from 5 years to 4 months, we will produce up to 100 drug blueprints per year, enabling real time adaptability within the precision medicine market. Using these methodologies, Polaris will build an IP portfolio of drug assets to license, sell, or develop internally.
We’re transforming health for people everywhere, by the fast creation of drug blueprints for all human proteins, disease pathways, genetic mutations and pathogens. We unite the powers of Quantum Computing, AI and Precision Medicine to search chemical space and create novel molecular drugs for specific proteins and diseases.
Total Funding: $2.1 M
Funding Stage: Seed
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2020
Jun 2021
- Polaris Quantum Biotech (POLARISqb) Partners with Auransa, Inc.
May 2021
- PolarisQB Announce Hiring of Pharmacologist Ian Reynolds as an Advisor
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Polaris Quantum Biotech
